1. Food and Drug Administration. Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Rockville MD: Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs; 1992.
2. Committee for Proprietary Medicinal Products. Note for guidance: Investigation of bioavailability and bioequivalence. London, UK: Committee for Proprietary Medicinal Products; 1991.
3. Food and Drug Administration. Average, population, and individual approaches to establishing bioequivalence. Draft Guidance for Industry. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research; October 1997.
4. Food and Drug Administration. Average, population and individual approaches to establishing bioequivalence. Draft Guidance for Industry. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research; August 1999.
5. Schall R, Williams RL for the Food and Drug Administration Individual Bioequivalence Working Group. Towards a practical strategy for assessing individual bioequivalence. J Pharmacokin Bio-pharm. 1996;24:133–149.